Declan Murphy on PSMA Molecules and the Motivation Behind the proPSMA Trial

Video

Declan Murphy discusses the motivation behind the proPSMA study and the emerging history of PSMA PET/CT to challenge conventional imaging at the 2020 SUO Meeting.

Transcription:

So PSMA as a molecule has been of interest for many years really because we know that its overexpressed in aggressive cancer especially castration-resistant prostate cancer. But what we’ve only had in the past 5 or 6 years is imaging agents which are useful to identify this overexpression of PSMA. The real breakthrough came 6 or 7 years ago when some German groups created small molecule ligands that can be used in a PET scanner to identify PSMA in a really quite striking, sensitive and specific manner.

These compounds came out of Germany in 2012/2013 and in Australia we had developed a program already with widespread use of PSMA all around the country really from 2014 onwards. We were beginning to see these striking images and it became very apparent that PSMA PET/CT was an obvious challenger to conventional imaging for staging newly diagnosed prostate cancer and also recurrent prostate cancer and so on. So, in 2017 we set up a prospective randomized trial called the proPSMA trial to compare conventional imaging with PSMA PET/CT for staging newly diagnosed, high-risk or unfavorable intermediate risk prostate cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content